Abstract
Naturalistic psychopharmacological study of efficacy and tolerability of agomelatine (valdoxan) in treatment of endogenous depressions (in the framework of schizophrenia, schizoaffective and bipolar disorder) in day patient department. Study sample consisted of 37 patient (59.4% female, mean age 41.6±3.7 years). CDS total score significantly reduced after 8 weeks of treatment 44.9% compared to baseline (р<0.001); HAM-D total score decreased on 51.3% compared to baseline (р<0.001). The proportion of responders at the 8th week of treatment was 54.1%. Agomelatine (valdoxan) had favorable safety profile. Follow-up study (up to 24 months) showed stable antidepressive effect and good tolerability profile of agomelatine (valdoxan). There was no withdrawal syndrome after treatment discontinuation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
